rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras(G12D) plasmids.
|
25077772 |
2014 |
rs587782329
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Lung tumors of 50 uranium miners in Germany were screened by restriction fragment length analysis for the putative hotspot mutation at codon 249 (Arg-->Met) previously detected in a significant fraction of miners from the Colorado Plateau, USA.
|
9067550 |
1997 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors.
|
23959381 |
2013 |
rs762846821
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors.
|
23959381 |
2013 |
rs113488022
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo.
|
24213573 |
2014 |
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo.
|
24213573 |
2014 |
rs772399455
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo.
|
24213573 |
2014 |
rs762846821
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Conversely, in lung tumour cell lines expressing Kras(G12D) and lacking p53, p53 restoration led to NF-kappaB inhibition.
|
19847165 |
2009 |
rs112295309
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Finally, we provide data consistent with immune infiltration having an important role in the acceleration of tumorigenesis in KRas(G12D) lung tumors following Scrib loss.
|
24276238 |
2014 |
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs8021944
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For SNPs rs8021944, rs1256061 and rs10146204, ERβ expression was higher according to the rank sum test in lung tumors from patients with at least one minor allele.
|
23619141 |
2013 |
rs1256061
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For SNPs rs8021944, rs1256061 and rs10146204, ERβ expression was higher according to the rank sum test in lung tumors from patients with at least one minor allele.
|
23619141 |
2013 |
rs10146204
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For SNPs rs8021944, rs1256061 and rs10146204, ERβ expression was higher according to the rank sum test in lung tumors from patients with at least one minor allele.
|
23619141 |
2013 |
rs1799793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Functional polymorphisms in XPD (Asp312Asn, rs1799793 and Lys751Gln, rs1052559), a protein required for nucleotide excision repair and with roles in p53-mediated apoptosis, were modestly associated with G:C-->T:A mutations in TP53 in lung tumors [Asp/Asn312 + Asn/Asn312 and/or Lys/Gln751 + Gln/Gln751 versus Asp/Asp312 + Lys/Lys751; odds ratio (OR) 2.73, 95% confidence interval (CI) 0.98-7.61], consistent with the role of this protein in repair of bulky carcinogen-DNA adducts.
|
15564288 |
2005 |
rs13181
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Functional polymorphisms in XPD (Asp312Asn, rs1799793 and Lys751Gln, rs1052559), a protein required for nucleotide excision repair and with roles in p53-mediated apoptosis, were modestly associated with G:C-->T:A mutations in TP53 in lung tumors [Asp/Asn312 + Asn/Asn312 and/or Lys/Gln751 + Gln/Gln751 versus Asp/Asp312 + Lys/Lys751; odds ratio (OR) 2.73, 95% confidence interval (CI) 0.98-7.61], consistent with the role of this protein in repair of bulky carcinogen-DNA adducts.
|
15564288 |
2005 |
rs1052559
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Functional polymorphisms in XPD (Asp312Asn, rs1799793 and Lys751Gln, rs1052559), a protein required for nucleotide excision repair and with roles in p53-mediated apoptosis, were modestly associated with G:C-->T:A mutations in TP53 in lung tumors [Asp/Asn312 + Asn/Asn312 and/or Lys/Gln751 + Gln/Gln751 versus Asp/Asp312 + Lys/Lys751; odds ratio (OR) 2.73, 95% confidence interval (CI) 0.98-7.61], consistent with the role of this protein in repair of bulky carcinogen-DNA adducts.
|
15564288 |
2005 |
rs121913529
|
|
|
0.080 |
GeneticVariation |
BEFREE |
However, a more rigorous test of the requirement for Notch signaling in lung oncogenesis, crossing the LSL-KRAS(G12D) mouse model with a transgenic with a similarly inducible global dominant-negative suppressor of Notch activity, LSL-DNMAML (dominant-negative mastermind-like), reveals no evidence of Notch pathway requirement for lung tumor initiation or growth in vivo.
|
21994468 |
2011 |
rs775514340
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, a more rigorous test of the requirement for Notch signaling in lung oncogenesis, crossing the LSL-KRAS(G12D) mouse model with a transgenic with a similarly inducible global dominant-negative suppressor of Notch activity, LSL-DNMAML (dominant-negative mastermind-like), reveals no evidence of Notch pathway requirement for lung tumor initiation or growth in vivo.
|
21994468 |
2011 |
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging.
|
31132309 |
2019 |